Serial entrepreneur with multiple successful exits; founded Colossal Biosciences to pursue de-extinction and genome engineering at planetary scale; previously built satellite and imaging companies with defense connections.
no scored calls yet — needs a stated position or a categorical verdict, with a matured window vs SPY
Ben Lamm argues Colossal's platform — genome engineering at scale, full DNA synthesis, and artificial wombs — has planetary-scale applications across invasive species control, human healthcare, and lab-grown materials, making it vastly undervalued despite $635M raised.
Vertical integration drove Colossal to acquire Viagen, the only US animal cloning company with 80% efficiency (vs 2% typical), securing the cloning layer for endangered species production and de-extinction pipeline.
Astromech applies a focused AI model to evolutionary genomics — leveraging Colossal's massive elephant dataset — to identify conserved cancer-resistance mechanisms (e.g., p53 overexpression) and predict drug targets across diseases, requiring far less compute than broad foundation models.